非朗格汉斯细胞组织细胞增生症(非LCH)是一组以组织细胞在组织中增殖为特征的疾病,被排除在LCH的诊断标准之外。青少年黄色肉芽肿(JXG)和良性头组织细胞增生症(BCH)是最常见的皮肤非LCH类型。这两种疾病在临床和组织学特征上都有相似之处,因此,它们可能很难区分。彻底的身体,皮肤镜,需要进行组织病理学检查以区分JXG和BCH。我们在此介绍两例罕见的非LCH患儿,与JXG和BCH一起呈现。两种情况的皮肤镜检查均显示为夕阳外观,虽然组织病理学检查显示JXG病例中有Touton巨细胞,BCH病例中大量淋巴细胞浸润。在前12周,两名患者均接受1%局部雷帕霉素治疗,然后是双方的申请,总持续时间为24周。因此,病变的大小明显缩小,导致患者的满意度。雷帕霉素是一种具有抗肿瘤活性的免疫抑制剂。雷帕霉素可用作JXG和BCH的替代非侵入性局部治疗选择。然而,需要长期观察来评估其有效性和副作用。
Non-Langerhans cell histiocytosis (non-LCH) is a group of diseases characterized by the proliferation of histiocytes in tissues that is excluded from the diagnostic criteria for LCH. Juvenile xanthogranuloma (JXG) and benign cephalic histiocytosis (BCH) are the most common types of cutaneous non-LCH. These two diseases share similarities in both clinical and histological features, therefore, they can be difficult to differentiate. Thorough physical, dermoscopic, and histopathological examinations are required to distinguish between JXG and BCH. We hereby present two rare cases of non-LCH in pediatric patients, presented with JXG and BCH. The dermoscopic examination of both cases showed a setting-sun appearance, while the histopathological examination revealed Touton giant cells in the JXG case, and massive lymphocyte infiltration in the BCH case. Both patients were treated with 1% topical rapamycin in a split-side comparison for the first 12 weeks, followed by applications on both sides for a total duration of 24 weeks. As a result, there was a significant reduction in the size of the lesion, leading to patient\'s satisfaction. Rapamycin is an immunosuppressive agent with antineoplastic activity. Rapamycin can be used as an alternative non-invasive topical treatment option for JXG and BCH. However, long-term observations are required to assess its effectiveness and side effects.